Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma

被引:16
|
作者
Emri, S
Akbulut, H [1 ]
Zorlu, F
Dinçol, D
Akay, H
Güngen, Y
Içli, F
机构
[1] Univ Hacettepe, Fac Med, Dept Chest Dis, TR-06100 Ankara, Turkey
[2] Univ Hacettepe, Fac Med, Dept Med Oncol, TR-06100 Ankara, Turkey
[3] Univ Hacettepe, Fac Med, Dept Pathol, TR-06100 Ankara, Turkey
[4] Ankara Univ, Fac Med, Dept Med Oncol, TR-06100 Ankara, Turkey
[5] Ankara Univ, Fac Med, Dept Chest Surg, TR-06100 Ankara, Turkey
关键词
mesothelioma; flow cytometry; aneuploidy; proliferation index; chemotherapy; erionite; asbestos;
D O I
10.1016/S0169-5002(00)00249-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant pleural mesothelioma (MPM) due to environmental exposure to asbestos and erionite is a relatively common cancer in Turkey. In this study, we investigated the value of flow cytometric (FCM) DNA analysis and other prognostic factors such as age and etiologic factor in the patients with MPM, treated with surgery combination chemotherapy radiotherapy. A total of 40 patients with a median age of 50 (range 30-68) were included in the Study. Twenty-nine patients had asbestos exposure in etiology, while 11 had fibrous zeolite (erionite). Paraffin-embedded tumor specimens were studied by FCM for DNA analysis. Twelve patients (30%) had aneuploid tumors and 28 (70%) had diploid ones. Mean S-phase fraction (SPF; %) was 9.1 +/- 1.1 and proliferation index (PI, SPF + G2/M phase; %) was 11.3 +/- 0.9. While the median overall survival (OS) was 10 +/- 2 months (6-14; 95% Q, 1-year survival rate was 45.2%, Only PI was found to be statistically significant for OS in univariate analysis (P = 0.013). PI was also found to be an independent prognostic factor for all patients (P = 0.035). Aneuploidy was significantly higher in erionite group Compared with asbestos group. Male predominance and poor survival were also prominent in erionite group, though not statistically significant. In conclusion, PI is an independent prognostic factor for patients with MPM and the biologic features of the disease may show differences with respect to different etiologies. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 50 条
  • [21] Effects of treatment regimens on survival in patients with malignant pleural mesothelioma
    Abakay, A.
    Abakay, O.
    Tanrikulu, A. C.
    Sezgi, C.
    Sen, H.
    Kaya, H.
    Kucukoner, M.
    Kaplan, M. A.
    Celik, Y.
    Senyigit, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2013, 17 (01) : 19 - 24
  • [22] Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients
    Fournel, Ludovic
    Charrier, Thomas
    Huriet, Maxime
    Iaffaldano, Amedeo
    Lupo, Audrey
    Damotte, Diane
    Arrondeau, Jennifer
    Alifano, Marco
    LUNG CANCER, 2022, 166 : 221 - 227
  • [23] Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed
    Takeuchi, Susumu
    Seike, Masahiro
    Noro, Rintaro
    Soeno, Chie
    Sugano, Teppei
    Zou, Fenfei
    Uesaka, Haruka
    Nishijima, Nobuhiko
    Matsumoto, Masaru
    Minegishi, Yuji
    Kubota, Kaoru
    Gemma, Akihiko
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (06) : 1886 - 1894
  • [24] Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma
    Creaney, Jenette
    Dick, Ian M.
    Segal, Amanda
    Musk, Arthur W.
    Robinson, Bruce W. S.
    LUNG CANCER, 2013, 82 (03) : 491 - 498
  • [25] Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
    Fujimoto, Nobukazu
    Ohnuma, Kei
    Aoe, Keisuke
    Hosono, Osamu
    Yamada, Taketo
    Kishimoto, Takumi
    Morimoto, Chikao
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S200 - S200
  • [26] Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers
    Creaney, Jenette
    Dick, Ian M.
    Musk, A. W.
    Olsen, Nola J.
    Robinson, Bruce W. S.
    BIOMARKERS, 2016, 21 (06) : 551 - 561
  • [27] Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma
    Hirayama, Noriko
    Tabata, Chiharu
    Tabata, Rie
    Maeda, Risa
    Yasumitsu, Akihiro
    Yamada, Shusai
    Kuribayashi, Kozo
    Fukuoka, Kazuya
    Nakano, Takashi
    RESPIRATORY MEDICINE, 2011, 105 (01) : 137 - 142
  • [28] Prognostic Biomarkers for Malignant Pleural Mesothelioma Treated with Chemotherapy
    Akgun, Hakan
    Metintas, Selma
    Ak, Guntulu
    Demirkol, Secil
    Aydin, Resat
    Isbilen, Murat
    Gure, Ali
    Metintas, Muzaffer
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1369 - S1369
  • [29] Haematologic parameters and their prognostic impact in malignant pleural mesothelioma
    Crolow, Catharina
    Blum, Torsten
    Kollmeier, Jens
    Gruff, Sergej
    Weiss, Timo
    Wurps, Henrik
    Thiel, Sebastian
    Schonfeld, Nicolas
    Bauer, Torsten T.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [30] Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients
    Fusco, Nicola
    Vaira, Valentina
    Righi, Ilaria
    Sajjadi, Elham
    Venetis, Konstantinos
    Lopez, Gianluca
    Cattaneo, Margherita
    Castellani, Massimo
    Rosso, Lorenzo
    Nosotti, Mario
    Clerici, Mario
    Ferrero, Stefano
    LUNG CANCER, 2020, 150 : 53 - 61